Phuturdex › Diseases › Paraproteinemia
Drugs in development · updated 30 October 2026
Paraproteinemia: drugs in development
As of 30 October 2026 there are 10 active clinical trials (recruiting or ongoing, phases I–III) on 13 drugs for paraproteinemia. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AnselamimabCAEL-101 | III | 2 | NCT04504825 |
| Nemtabrutinib | I–II | 1 | NCT03162536 |
| KLN-1010 | I | 1 | NCT07075185 |
| OriCAR-017 | I | 1 | NCT06271252 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DexamethasoneDexametasone, Dextenza | III | 4 | NCT04504825 |
| BortezomibVelcade, Bortezomib Hospira® | III | 2 | NCT04504825 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 2 | NCT04504825 |
| DaratumumabDarzalex | I–II | 3 | NCT05581875 |
| Belantamab mafodotinGSK2857916, Blenrep® | I–II | 2 | NCT05573802 |
| IsatuximabIsatuximab SAR650984, Sarclisa Escena® | II | 1 | NCT04614558 |
| LenalidomideRevlimid, lenalinomide | I–II | 1 | NCT05573802 |
| NirogacestatOgsiveo® | I–II | 1 | NCT05573802 |
| PomalidomideImnovid, Pomalyst® | I–II | 1 | NCT05581875 |
Sorted by most advanced phase and number of active trials.
All 13 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Multiple myeloma 272 drugs
- Waldenstrom Macroglobulinemia 51 drugs
- Lymphoma 252 drugs
- Non-Hodgkin lymphoma 269 drugs
- Hematologic neoplasm 216 drugs
- Immunoglobulin Light-chain Amyloidosis 27 drugs
- Smoldering Multiple Myeloma 24 drugs
- Chronic lymphocytic leukemia 137 drugs
- Follicular lymphoma 144 drugs
- Lymphoma, B-Cell, Marginal Zone 86 drugs
- Mantle cell lymphoma 108 drugs
- Neoplasm 671 drugs
Broader categories
- Immune System Diseases 54 drugs
- Immunoproliferative disorder 16 drugs
- Hematologic Diseases 57 drugs
- Blood protein disease 9 drugs
- Lymphoproliferative disorders 51 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D010265 “Paraproteinemias”.